The Incidence and Characteristics of Misdiagnosed Covid-19 Patients with Dengue Fever Infections at Udayana University Hospital in 2020-2021
Downloads
The rise in dengue fever in recent decades combined with the emergence of COVID-19 at the end of 2019, has created new challenges in the healthcare sector. This research is a descriptive study with a cross-sectional research design and using medical record data at Udayana University Hospital in 2020–2021. According to the study, 1.22% cases of misdiagnosis out of a total of 2365 suspected cases of COVID-19 were found at Udayana University. The majority of cases of misdiagnosis involved people older than 60 years, namely 7 people (24.1%) and were dominated by men, namely 17 people (58.6%). The most common symptoms found are fever, cough, shortness of breath, headache, and malaise, According to laboratory results, dominant patients have thrombocytopenia, followed by high alanine transaminase (ALT), high aspartate transaminase (AST), and leukopenia. The appearance of thrombocytopenia in cases of COVID-19 with dengue fever is the result of suppressed platelet synthesis due to virus induction which causes bone marrow suppression and platelet clearance. Leukopenia and leukocytosis may coexist with lymphopenia as an indicator of disease severity. The similarity of symptoms and laboratory results between COVID-19 and dengue fever allows for misdiagnosis that will affect the patient's management. Therefore, the aim of this study is to determine the misdiagnosis rate of COVID-19 with dengue fever at Udayana University Hospital in 2020–2021, so that it can reduce misdiagnosis of the disease.
Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol [Internet]. 2020 Jun 1 [cited 2021 Sep 20];215:108427. Available from: /pmc/articles/PMC7169933/
Li H, Liu S-M, Yu X-H, Tang S-L, Tang C-K. Coronavirus disease 2019 (COVID-19): current status and future perspectives. Int J Antimicrob Agents [Internet]. 2020 May 1 [cited 2021 Sep 20];55(5):105951. Available from: /pmc/articles/PMC7139247/
Rauf A, Abu-Izneid T, Olatunde A, Khalil AA, Alhumaydhi FA, Tufail T, et al. COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. Int J Environ Res Public Health [Internet]. 2020 Nov 1 [cited 2021 Oct 15];17(21):1–32. Available from: /pmc/articles/PMC7662254/
Lotfi M, Hamblin MR, Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta [Internet]. 2020 Sep 1 [cited 2021 Sep 20];508:254. Available from: /pmc/articles/PMC7256510/
Cascella M, Rajnik M, Aleem A, Dulebohn SC, Napoli R Di. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls [Internet]. 2021 Jul 30 [cited 2021 Oct 15]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK554776/
WHO. Coronavirus disease (COVID-19) pandemic [Internet]. WHO. 2020 [cited 2022 Nov 6]. Available from: https://www.who.int/europe/emergencies/situations/covid-19
Tantawichien T, Thisayakorn U. Dengue. Neglected Trop Dis - South Asia [Internet]. 2017 [cited 2021 Sep 20];329. Available from: /pmc/articles/PMC7123783/
Khetarpal N, Khanna I. Dengue Fever: Causes, Complications, and Vaccine Strategies. J Immunol Res [Internet]. 2016 [cited 2021 Sep 20];2016. Available from: /pmc/articles/PMC4971387/
Schaefer TJ, Panda PK, Wolford RW. Dengue Fever. BMJ Best Pract [Internet]. 2021 Aug 11 [cited 2021 Oct 3];5–6. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430732/
WHO. Dengue and severe dengue [Internet]. WHO. 2021 [cited 2021 Oct 2]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue
Smith DS. Dengue [Internet]. Medscape. 2019 [cited 2021 Sep 29]. Available from: https://emedicine.medscape.com/article/215840-overview#a4
Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nat 2013 4967446 [Internet]. 2013 Apr 7 [cited 2022 Dec 14];496(7446):504–7. Available from: https://www.nature.com/articles/nature12060
Harapan H, Michie A, Mudatsir M, Sasmono RT, Imrie A. Epidemiology of dengue hemorrhagic fever in Indonesia: analysis of five decades data from the National Disease Surveillance. BMC Res Notes [Internet]. 2019 Jun 20 [cited 2021 Oct 2];12(1). Available from: /pmc/articles/PMC6587249/
WHO. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. WHO. 2022 [cited 2022 Dec 30]. Available from: https://covid19.who.int/
Khairunisa SQ, Amarullah IH, Churrotin S, Fitria AL, Amin M, Lusida MI, et al. Potential Misdiagnosis between COVID-19 and Dengue Infection Using Rapid Serological Test. Infect Dis Rep [Internet]. 2021 Jun 1 [cited 2021 Dec 17];13(2):540. Available from: /pmc/articles/PMC8293083/
Jayarajah U, Lahiru M, de Zoysa I, Seneviratne SL. Dengue Infections and the Surgical Patient. Am J Trop Med Hyg [Internet]. 2021 Jan 6 [cited 2022 Sep 16];104(1):52. Available from: /pmc/articles/PMC7790109/
Masyeni S, Santoso MS, Widyaningsih PD, Asmara DW, Nainu F, Harapan H, et al. Serological cross-reaction and coinfection of dengue and COVID-19 in Asia: Experience from Indonesia. Int J Infect Dis [Internet]. 2021 Jan 1 [cited 2021 Sep 20];102:152. Available from: /pmc/articles/PMC7585717/
Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, et al. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses. Clin Infect Dis An Off Publ Infect Dis Soc Am [Internet]. 2021 Oct 5 [cited 2021 Dec 17];73(7):e2444–9. Available from: /pmc/articles/PMC7454334/?report=abstract
Santoso MS, Masyeni S, Haryanto S, Yohan B, Hibberd ML, Sasmono RT. Assessment of dengue and COVID-19 antibody rapid diagnostic tests cross-reactivity in Indonesia. Virol J [Internet]. 2021 Dec 1 [cited 2021 Dec 17];18(1):1–5. Available from: https://virologyj.biomedcentral.com/articles/10.1186/s12985-021-01522-2
Kembuan GJ. Dengue serology in Indonesian COVID-19 patients: Coinfection or serological overlap? IDCases [Internet]. 2020 Jan 1 [cited 2022 Nov 7];22. Available from: /pmc/articles/PMC7403131/
Tsheten T, Clements ACA, Gray DJ, Adhikary RK, Wangdi K. Clinical features and outcomes of COVID-19 and dengue co-infection: a systematic review. BMC Infect Dis [Internet]. 2021 Dec 1 [cited 2021 Sep 20];21(1). Available from: /pmc/articles/PMC8327042/
Hannan TB, Hossain Z, Hasan MN, Khan AH, Alam MR, Rahman MM, et al. Clinical and laboratory characteristics of dengue and COVID-19 coinfected patients in Dhaka, Bangladesh. Trans R Soc Trop Med Hyg [Internet]. 2022 Apr 20 [cited 2022 Nov 7]; Available from: /pmc/articles/PMC9047248/
Henrina J, Putra ICS, Lawrensia S, Handoyono QF, Cahyadi A. Coronavirus Disease of 2019: a Mimicker of Dengue Infection? Sn Compr Clin Med [Internet]. 2020 Aug [cited 2022 Nov 9];2(8):1109. Available from: /pmc/articles/PMC7356135/
Prapty CNBS, Rahmat R, Araf Y, Shounak SK, Noor-A-Afrin, Rahaman TI, et al. SARS"CoV"2 and dengue virus co"infection: Epidemiology, pathogenesis, diagnosis, treatment, and management. Rev Med Virol [Internet]. 2022 [cited 2022 Nov 9]; Available from: /pmc/articles/PMC9111128/
Rosso F, Parra-Lara LG, Agudelo-Rojas OL, Martinez-Ruiz DM. Differentiating Dengue from COVID-19: Comparison of Cases in Colombia. Am J Trop Med Hyg [Internet]. 2021 Sep 1 [cited 2022 Nov 9];105(3):745. Available from: /pmc/articles/PMC8592361/
Copyright (c) 2023 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
